LY3127804 + ramucirumab + paclitaxel

LY3127804 + ramucirumab + paclitaxel is an experimental **combination therapy** comprising three agents: LY3127804, a humanized monoclonal antibody targeting angiopoietin-2 (Ang-2); ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2); and paclitaxel, a chemotherapy agent that stabilizes microtubules. LY3127804 aims to inhibit angiogenesis via Ang-2 blockade, while ramucirumab blocks VEGFR2-mediated vascular signaling, and paclitaxel disrupts tumor cell division by hyperstabilizing microtubules. The combination is under clinical investigation primarily for advanced or metastatic solid tumors, particularly in oncology settings where targeting both angiogenic pathways and tumor proliferation may yield synergistic anti-cancer effects[1][2].